• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    10/25/22 8:08:16 AM ET
    $ACET
    $ACRX
    $AGTC
    $ARAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email

    Gainers

    • Taysha Gene Therapies (NASDAQ:TSHA) stock increased by 36.4% to $2.06 during Tuesday's pre-market session. The market value of their outstanding shares is at $84.6 million.
    • Medpace Hldgs (NASDAQ:MEDP) shares moved upwards by 29.3% to $205.13. The market value of their outstanding shares is at $6.3 billion. As per the news, the Q3 earnings report came out yesterday.
    • PhaseBio Pharmaceuticals (NASDAQ:PHAS) shares moved upwards by 19.94% to $0.17. The market value of their outstanding shares is at $8.4 million.
    • Revelation Biosciences (NASDAQ:REVB) shares increased by 15.21% to $0.29. The company's market cap stands at $6.7 million.
    • Aravive (NASDAQ:ARAV) stock rose 13.08% to $0.9. The market value of their outstanding shares is at $27.4 million.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) stock rose 10.93% to $0.13. The company's market cap stands at $16.2 million.

    Losers

    • Biotricity (NASDAQ:BTCY) shares fell 9.9% to $1.0 during Tuesday's pre-market session. The market value of their outstanding shares is at $51.8 million.
    • Applied Genetic Techs (NASDAQ:AGTC) shares fell 7.31% to $0.36. The company's market cap stands at $24.4 million.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) shares fell 6.2% to $0.2. The company's market cap stands at $29.4 million.
    • Bone Biologics (NASDAQ:BBLG) stock fell 5.96% to $0.47. The market value of their outstanding shares is at $6.6 million.
    • Adicet Bio (NASDAQ:ACET) stock decreased by 5.72% to $15.01. The market value of their outstanding shares is at $600.8 million.
    • Neogen (NASDAQ:NEOG) stock fell 4.99% to $10.68. The company's market cap stands at $2.3 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACET
    $ACRX
    $AGTC
    $ARAV

    CompanyDatePrice TargetRatingAnalyst
    Medpace Holdings Inc.
    $MEDP
    3/6/2026$500.00Underweight → Equal Weight
    Barclays
    Medpace Holdings Inc.
    $MEDP
    3/3/2026$522.00Outperform
    RBC Capital Mkts
    Medpace Holdings Inc.
    $MEDP
    2/18/2026$419.00Sell → Hold
    TD Cowen
    Medpace Holdings Inc.
    $MEDP
    2/13/2026$560.00Hold → Buy
    Jefferies
    Medpace Holdings Inc.
    $MEDP
    2/10/2026$564.00Neutral → Outperform
    Robert W. Baird
    Medpace Holdings Inc.
    $MEDP
    11/13/2025$600.00Market Perform
    BMO Capital Markets
    Taysha Gene Therapies Inc.
    $TSHA
    10/21/2025$13.00Strong Buy
    Raymond James
    Medpace Holdings Inc.
    $MEDP
    10/2/2025$425.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $ACET
    $ACRX
    $AGTC
    $ARAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $252 worth of shares (23 units at $10.94) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/17/26 3:12:55 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $486 worth of shares (49 units at $9.93) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    2/2/26 4:36:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,279 worth of shares (137 units at $9.33) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    1/16/26 9:04:01 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACET
    $ACRX
    $AGTC
    $ARAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medpace upgraded by Barclays with a new price target

    Barclays upgraded Medpace from Underweight to Equal Weight and set a new price target of $500.00

    3/6/26 8:19:59 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    RBC Capital Mkts initiated coverage on Medpace with a new price target

    RBC Capital Mkts initiated coverage of Medpace with a rating of Outperform and set a new price target of $522.00

    3/3/26 8:27:50 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace upgraded by TD Cowen with a new price target

    TD Cowen upgraded Medpace from Sell to Hold and set a new price target of $419.00

    2/18/26 7:50:53 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ACET
    $ACRX
    $AGTC
    $ARAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 2, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 156,870 shares of the Company's common stock and an option to purchase 134,460 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement

    3/6/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neogen Announces Sale of Genomics Business to Zoetis

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. ("Zoetis"), the world's leading animal health company, for $160 million, subject to customary closing adjustments. The planned divestiture, which had been previously announced, was part of the company's portfolio review strategy to simplify the business and focus on core strategic markets. The transaction is expected to close by the end of the first half of the Company's 2027 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds from the transaction are expected

    3/2/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation

    Acquisition strengthens Zoetis' leadership in Precision Animal Health by integrating Neogen's global genomics capabilities, expanding predictive insights and individualized care worldwide Zoetis Inc. (NYSE:ZTS) the world's leading animal health company, today announced it has entered into a definitive agreement with Neogen Corporation (NASDAQ:NEOG) ("Neogen") to acquire Neogen's animal genomics business for $160 million, subject to customary closing adjustments. This acquisition aligns directly with Zoetis' strategy to drive future livestock innovation through genomics, reinforcing its commitment to livestock producers worldwide and advancing its Precision Animal Health portfolio. By inte

    3/2/26 7:00:00 AM ET
    $NEOG
    $ZTS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACET
    $ACRX
    $AGTC
    $ARAV
    SEC Filings

    View All

    Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

    3/9/26 7:43:03 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Bone Biologics Corp

    10-K - Bone Biologics Corp (0001419554) (Filer)

    3/2/26 4:35:54 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/26/26 4:25:26 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $ACRX
    $AGTC
    $ARAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Smethurst Dominic sold $50,601 worth of shares (6,097 units at $8.30), decreasing direct ownership by 6% to 89,790 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    3/4/26 4:30:18 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel & Corp. Secy. Ewald Stephen P exercised 3,500 shares at a strike of $138.87, increasing direct ownership by 26% to 16,843 units (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    2/18/26 4:59:18 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Operating Officer Hodgson Ian sold $6,253 worth of shares (847 units at $7.38), decreasing direct ownership by 2% to 51,080 units (SEC Form 4)

    4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

    2/18/26 4:32:02 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $ACRX
    $AGTC
    $ARAV
    Financials

    Live finance-specific insights

    View All

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

    Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1% from net new business awards of $529.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Fourth quarter of 2025 GAAP net income was $135.1 million, or $4.67 per diluted share, versus GAAP net income of $117.0 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 19.1% and 21.8% for the fourth quarter

    2/9/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $ACET
    $ACRX
    $AGTC
    $ARAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 6:41:20 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    $ACRX
    $AGTC
    $ARAV
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Mike Nassif as CEO and President

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Mike Nassif as its new Chief Executive Officer and President, effective August 11, 2025. He also will join Neogen's Board of Directors at that time. Mr. Nassif succeeds John Adent who will, as previously announced, step down after an eight-year career at the company. Mr. Nassif brings a wealth of experience and a proven track record of success in the healthcare and diagnostics industry. Mr. Nassif joins Neogen from Siemens Healthineers, where he was Global President of the Point-of-Care Diagnostics business and instrumental in driving significant growth. "I am very exci

    7/24/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care